计量化学疗法诱导癌细胞的代谢重编程,调节成熟的调节性树突细胞功能,以刺激抗瘤免疫力
Zhenji Deng1, Chuqing Zhang1, Hanmiao Wei1
1Sun Yat-sen University Cancer Center Guangzhou China.
Cancer research
|March 5, 2026
概括
计量化学疗法通过增强CD8+T细胞来增强抗瘤免疫力. 这种治疗重新编程瘤细胞释放阿斯巴拉金,然后调节树突细胞以改善免疫记忆.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 代谢重编程 代谢重编程
背景情况:
- 化疗的疗效依赖于诱导抗瘤免疫力.
- 了解化疗的免疫调节是优化治疗的关键.
研究的目的:
- 为了研究计量化学疗法如何调节抗瘤免疫反应.
- 为了阐明介质化学疗法诱导的免疫记忆背后的机制.
主要方法:
- 在瘤模型中进行计量化学疗法.
- 对T细胞反应和树突细胞活动的分析.
- 研究代谢重编程和分子信号通路 (ATF4,阿斯巴拉金,AXL,PD-L1).
主要成果:
- 计量化学疗法诱导了强大的CD8+T细胞依赖的抗瘤免疫记忆.
- 持续的ATF4激活导致瘤细胞代谢重编程并增加了阿斯巴拉金的释放.
- 在成熟调节性树突细胞 (mregDCs) 上与AXL结合的阿斯巴拉金抑制了AXL活性和PD-L1表达.
- 降低mregDCs上的PD-L1促进了类似记忆的CD8+T细胞的产生.
结论:
- 计量化学疗法通过调节mregDCs有效地产生抗瘤免疫记忆.
- 涉及瘤细胞应激,阿斯巴拉金释放和mregDC重编程的途径对于免疫记忆形成至关重要.
- 这项研究提供了通过利用免疫调节效应来优化化疗策略的理由.
相关概念视频
Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Electron Transport Chain: Complex I and II
19.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.3K
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K


